Monday, Nov. 16, 2026 · about a 5-minute read
Good morning. Yesterday a launch tower's arms caught a Starship coming home from orbit for the first time, one knee shot cut arthritis pain by 61% in a trial, a Utah hot-rock power plant passed a gigawatt in orders and Google said its robot brain can now sweep and fold. Today, the parts list for ending reading glasses, and the one part still missing.
The big one
Throw Away the Reading Glasses? Science Has Most of the Parts. One Is Missing. Some Assembly Required #8 takes on presbyopia, the close-up blur of middle age that comes as the lens inside the eye stiffens and stops changing shape. Most of a fix already exists in pieces: eye drops on pharmacy shelves, overnight contact lenses that reshape the front of the eye, a replacement lens that changes shape like a young one, and tiny implants that give the eye's focusing muscle more room. The missing part would make an aging lens soft again, and two teams have tried: a Novartis eye drop that helped in one mid-stage trial before missing in a larger one, and a Swiss laser that has restored focusing in pig eyes.
Why it matters: one drugmaker's chief executive put presbyopia at about 90% of Americans over 45. Today's fixes last a day or a night at a time, or arrive with cataract surgery late in life; a lens made soft again would bring back the close focus the eye had at 25. Our odds on each part, and on the whole machine, are below the line. Read it →
Yesterday on the site
The End of Aging
One Week of a Drug Rewound the Fertility Clock in Old Mice: a seven-day course of the peptide elamipretide made old female mice's eggs fertilize better and gave them bigger litters for a month afterward, and eggs from women 35 and older matured better with it in a dish (in mice; secondary report of an Aging Cell paper).
A Replacement Lens That Focuses Like a Young Eye Still Worked After Three Years: Atia Vision says its shape-changing OmniVu lens, implanted during cataract surgery, gave its first 19 patients clear far, middle and near vision without glasses three years on, and a U.S. study is under way (company report).
Tiny Eye Implants to End Reading Glasses Get a Second Shot at U.S. Approval: VisAbility's implants, placed in the white of the eye and already sold in Europe, are back in a new 33-person U.S. trial that began June 2, after an FDA panel voted against them in 2020.
The End of Disease
Faster Cancer Drug Picks: AI and Lab-Grown Tumor Copies Called 7 of 8 Trials: Paris start-up Orakl Oncology tests drugs on lab-grown copies of patients' tumors and trains an AI on the results; looking back at eight finished trials, it picked the better treatment seven times, and it just raised $34 million (preprint, not peer reviewed).
One Knee Shot Cut Arthritis Pain by 61%, Nearly Triple the Placebo: in 113 people with moderate knee arthritis, one shot of donated cord-blood stem cells in a cartilage scaffold cut pain about 61% at six months on its middle dose, against 23% on placebo (mid-stage trial; secondary report of a conference abstract).
Superhuman
A Brain Implant Without Skull Surgery Pauses Trials to Build a Better Cable: Synchron, whose Stentrode is threaded up through a blood vessel instead of placed through the skull, paused enrollment in its wireless next-generation trials over a faulty cable and is bringing the cable's design and manufacturing in-house; it says no safety issue was found (company claim, secondary report).
Robots & Self-Driving
Robot Housekeepers Get Closer: Google Says Its New Robot Brain Can Now Sweep and Fold: Google DeepMind says Gemini Robotics 2.5 swept trash into a dustpan 52% of the time, up from 0% for the earlier version, hung a cardigan 62% of the time, and helped a humanoid load car parts correctly 96% of the time at two Mercedes-Benz plants (company figures, not independently checked).
To the Stars
Cheaper Spaceflight Just Caught a Break: SpaceX Plucks a Starship Out of the Sky After Orbit: after about 22 hours circling Earth and 26 Starlink satellites released, SpaceX's Starship upper stage flew home Nov. 14 and the launch tower's arms caught it, a first; the booster missed its own catch and splashed down (per Space.com and Aviation Week).
Supplies for a Moon Base Every Five Weeks: NASA Plans 10 Landings a Year: NASA plans robotic cargo landings on the Moon about 10 times a year from 2028 and raised its first delivery contract pool to $4.2 billion from $2.6 billion; this year's three landers moved to 2027 (secondary report of NASA's Nov. 7 briefing).
Limitless Energy
Clean Power That Never Sleeps Just Topped a Gigawatt in Orders: Fervo Energy's Utah hot-rock plant has 36 megawatts running, and binding contracts to buy its power reached 1,054 megawatts, Google's 396 included (company figures).
Limitless Clean Power From Fusion Has 26 Plants Planned and $21.9 Billion Behind It: the UN's nuclear agency counts 92 private fusion companies, $21.9 billion in committed money and 26 planned fusion power plants, with target dates from the early 2030s to the 2050s (via an industry notice and a secondary report).
Sci-Fi Tech
India Will Build Its Own Subway-Digging Giants, Its Maker Says: state-owned BEML says its first homegrown tunnel-boring machine, 3.5 to 6.5 meters across, the sizes used for subways and water tunnels, could arrive about 22 months after an order; no order or prototype yet (secondary report quoting its chairman).
By the numbers
22 hours: how long Starship's upper stage circled Earth before flying home to be caught by its launch tower.
1,054 megawatts: the power buyers have signed binding contracts for from Fervo's hot-rock plants, up from 658 three months earlier.
61%: the drop in knee arthritis pain six months after one stem-cell shot, against 23% on placebo, in a 113-person trial.
7 of 8: finished cancer trials in which Orakl's tumor copies and AI picked the better treatment, looking back (preprint).
New on the odds board
Yesterday's posts put fresh odds on a flown Starship upper stage flying a second time, NASA landing cargo on the Moon 10 times in one year, Fervo's Google-backed hot-rock phase running, elamipretide being tested in women for ovarian aging, tumor copies and AI calling a cancer trial before it reads out, a home robot reliably doing everyday chores on its own, a one-shot stem-cell knee therapy winning approval and a fusion machine putting electricity on a U.S. grid. The whole board lives on the calculator.
On the calendar
Nov. 17 to 19: FAA public meetings on SpaceX's request to fly Starship far more often from South Texas.
Nov. 18: China's license requirement for exporting tunnel-boring machines takes effect.
No earlier than Dec. 10: Starship's 16th flight, which could be the first Starship launch from pad 39A in Florida (as reported).
By Jan. 1, 2027: Fervo's next two Utah blocks are due to be commercial, finishing the plant's first phase at about 100 megawatts.
January 2027, at the earliest: Astrobotic's Griffin Moon lander.
First quarter of 2027: LG's two-legged humanoid, built with NVIDIA, is due to be unveiled (company claim).
2028: NASA's pace of 10 Moon cargo deliveries a year is due to begin.
The story we're following
Digital patients: computer copies of patients, which could shorten the wait for nearly every new medicine. One step toward them landed yesterday. Orakl Oncology grows small lab copies of real patients' tumors, tests drugs on them and feeds the results to an AI, and looking back at eight finished cancer trials, it picked the better treatment seven times. The decisive step comes next: a forecast published before a trial reads out, then checked against the result. If forecasts like that hold up, people with cancer could start on the drug most likely to work for them, and drugmakers could spot losing trials before patients spend years in them.
Quote of the day
"Other small machines might be permanently incorporated in the body to assist some inadequately-functioning organ." — Richard Feynman, the physicist, in his talk "There's Plenty of Room at the Bottom," given Dec. 29, 1959, at Caltech and printed in Caltech's Engineering and Science in February 1960. Sixty-six years later, tiny implants that give the eye's focusing muscle room are back in a U.S. trial, and a brain implant rides in through a blood vessel.
Coming up
Already up this morning: science has most of the parts to end reading glasses, and one is missing. Later today: at 9 AM, Poland's fast-train future goes underground as a 430-ton drill head drops into Łódź; and at 11 AM, scientists grew tiny human eye lenses in a dish to test drugs for cataracts.
Until next time
That's today in the future. If someone you know would want to wake up to this, forward it to them, and if you're reading a forward, subscribe here. It's free every morning.



